| Previous Close | 0.1250 |
| Open | 0.1250 |
| Bid | 0.1150 x N/A |
| Ask | 0.1200 x N/A |
| Day's Range | 0.1200 - 0.1250 |
| 52 Week Range | 0.0700 - 0.1600 |
| Volume | 53,100 |
| Avg. Volume | 146,822 |
| Market Cap | 21.051M |
| Beta (5Y Monthly) | -0.11 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0230 |
| Earnings Date | Aug. 28, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 0.45 |
- Business Wire
MedX Health Corp. Announces Management Changes and Increased Focus on SIAscopyâ„¢ on DermSecureâ„¢
MedX Health Corp. ("MedX" or the "Company") (TSX-V: MDX) announced that it has completed management changes to enhance its focus on its dermatological services and products ("DSP") including DermSecureâ„¢ and SIAscopyâ„¢.
- Business Wire
MedX Health Corp. Announces Postponement of the Release of Second Quarter Interim Financial Statements and Related Disclosure Due to COVID-19 Related Delays
MedX Health Corp. (MDX: TSXV) ("the Company"), announces that there will be a delay in the filing of its Interim Financial Statements and accompanying Management’s Discussion and Analysis, and related CEO and CFO certifications for the Second Quarter ended June 30, 2020 (collectively "Interim Filings") due to COVID-19 related delays.
- Business Wire
MedX Announces Issuance of Shares in Connection with Advertising Services Agreement
MedX Health Corp. ("MedX") (TSX-V: MDX) announces that pursuant the agreement for an online marketing and awareness program through AGORACOM, that was announced in a Press Release dated June 1, 2020, it has settled the second payment to AGORACOM, in the amount of $13,560, by issuance on August 12, 2020, of 104,307 shares at an issue price of $0.13 per share. The issue price of the shares was determined by using the undiscounted closing price of the Shares of the Company on the TSX Venture Exchange on August 11, 2020, being the last trading day before the date of issuance. The shares were issued pursuant to the prospectus exemption contained in section 2.24 of National Instrument 45-106 Prospectus Exemptions, and are not subject to trading restrictions pursuant to the provisions of National Instrument 45-102, Resale of Securities since the criteria contained in NI 45-102 2.6(3) are met.
